Autolus Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Autolus's estimated annual revenue is currently $66.2M per year.
- Autolus's estimated revenue per employee is $155,000
- Autolus's total funding is $281.7M.
- Autolus has 427 Employees.
- Autolus grew their employee count by 21% last year.
- Autolus currently has 8 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Autolus?
Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. We are building a leading biotechnology company focussed on the development and commercialisation of engineered T-cell therapies for haematological and solid tumours. Autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient's own cells.keywords:N/A
Number of Employees
Employee Growth %
In a note, analysts at US broker Stifel noted a large block trade of 7.4mln Autolus shares on Thursday could only have come from the Woodford ...
On Thursday, shares of Autolus Therapeutics plc (NASDAQ:AUTL) marked $11.93 per share versus a previous $9.80 closing price. With having ...
Good morning, ladies and gentlemen, and welcome to the Autolus Therapeutics second-quarter 2019 financial results conference call.
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|